Seeger Weiss represented investors relating to misrepresentations and omissions concerning prescription medications Bextra and Celebrex in this federal securities fraud action against drugmaker Pfizer. Partner Dave Buchanan played a leading role in developing the expert slate to overcome Pfizer’s early science challenge, led with co-founding partner Christopher Seeger plaintiff’s presentation and examinations during the seven-day Daubert hearing. Following pre-trial motion practice and ensuing appeals, the case settled, resulting in a $486 million cash settlement fund for the class of aggrieved investors.
Bextra and Celebrex Securities Fraud
Investors alleged that drugmaker Pfizer violated federal securities laws by making false, misleading or incomplete statements regarding the cardiovascular risks of Celebrex and Bextra. Seeger Weiss helped secure a $486 million settlement on behalf of the investors.
Prior results do not guarantee or predict a similar outcome in any future matter.